Pediatric ALK+ Anaplastic Large Cell Lymphoma With t(3;8)(q26.2;q24) Translocation and c-myc Rearrangement Terminating in a Leukemic Phase

Monaco, Sara; Tsao, Lawrence; Vundavalli, Murty V.; Nandula, Subhadra; Donovan, Virginia; Oesterheld, J.; Bhagat, Govind; Alobeid, Bachir

Pediatric ALK‐positive anaplastic large cell lymphoma (ALK+ ALCL) is usually associated with a favorable prognosis. ALK+ ALCL associated with a leukemic phase is uncommon, but has been associated with an aggressive clinical course and unfavorable prognosis. Overexpression of c‐myc has been shown to be a consistent finding in ALK+, but not ALK‐negative ALCL (ALK− ALCL), and the c‐myc gene is considered a downstream target of deregulated ALK signaling. We describe a pediatric ALK+ ALCL with a leukemic phase at relapse. Similar to other rare cases described in the literature, it followed an aggressive clinical course despite multiple regimens of chemotherapy and bone marrow transplantation. Lymphoma cells showed aberrant ALK expression and c‐myc overexpression. In addition to the characteristic t(2;5)(p23;q35) translocation, a t(3;8)(q26.2;q24) translocation was also present, and c‐myc gene rearrangement was confirmed by FISH analysis. The findings in this case demonstrate the association of peripheral blood leukemic involvement and aggressive clinical course, and suggest that other factors, such as c‐myc rearrangement, may be responsible for the aggressive clinical behavior in ALK+ ALCL.


  • thumnail for Monaco S et al Am J Hematol 2007.pdf Monaco S et al Am J Hematol 2007.pdf application/pdf 153 KB Download File

Also Published In

American Journal of Hematology

More About This Work

Academic Units
Pathology and Cell Biology
Published Here
February 12, 2020